Literature DB >> 8947318

Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer.

F K Del Boca1, H R Kranzler, J Brown, P F Korner.   

Abstract

Compliance with the medication regimen in treatment trials for alcoholism appears to be a key determinant of treatment outcome. However, there is no consensus as to the best method to assess medication compliance. This study examines the feasibility of using ultraviolet light detection of a urinary riboflavin tracer to determine compliance with medication therapy. Six sets of urine specimens (with n ranging from 15 to 38) were rated independently by two judges. Test-retest reliability was high: 90 and 95% agreement for two judges. Inter-rater reliability ranged from 73 to 95% agreement between judges (mean = 88%), with correspondence kappa values ranging from 0.46 to 0.85 (mean = 0.69). Diaries, capsule counts, and spectrofluorimetric data were used to validate judges' ratings in four trials, including one in which subjects were alcohol-dependent participants in one of three pharmacotherapy trials. Rating accuracy was influenced by dosage, time interval between ingestion and urine collection, and previous dosing. Overall, ratings tended to be accurate, with incorrect judgments limited to specimens with low concentrations of urinary riboflavin. The results indicate that ultraviolet light detection of urinary riboflavin is a useful method for the assessment of patient compliance with medication regimens, including compliance of patients assigned to receive placebo in clinical trials of medications for alcoholism treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947318     DOI: 10.1111/j.1530-0277.1996.tb01142.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  55 in total

1.  Developing and validating a human laboratory model to screen medications for smoking cessation.

Authors:  Sherry A McKee; Andrea H Weinberger; Julia Shi; Jeanette Tetrault; Sabrina Coppola
Journal:  Nicotine Tob Res       Date:  2012-04-06       Impact factor: 4.244

2.  Riboflavin as an oral tracer for monitoring compliance in clinical research.

Authors:  V M Sadagopa Ramanujam; Karl E Anderson; James J Grady; Fatima Nayeem; Lee-Jane W Lu
Journal:  Open Biomark J       Date:  2011

3.  Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback.

Authors:  Joy M Schmitz; Shelly L Sayre; Angela L Stotts; Jennifer Rothfleisch; Marc E Mooney
Journal:  J Behav Med       Date:  2005-04

4.  Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.

Authors:  Daniel J O Roche; Spencer Bujarski; Emily Hartwell; ReJoyce Green; Lara A Ray
Journal:  Pharmacol Biochem Behav       Date:  2015-04-28       Impact factor: 3.533

5.  Kudzu root extract does not perturb the sleep/wake cycle of moderate drinkers.

Authors:  Bethany K Bracken; David M Penetar; Robert Ross Maclean; Scott E Lukas
Journal:  J Altern Complement Med       Date:  2011-10       Impact factor: 2.579

6.  Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.

Authors:  Spencer Bujarski; James MacKillop; Lara A Ray
Journal:  Exp Clin Psychopharmacol       Date:  2012-03-19       Impact factor: 3.157

7.  Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.

Authors:  George A Kenna; Carolina L Haass-Koffler; William H Zywiak; Steven M Edwards; Michael B Brickley; Robert M Swift; Lorenzo Leggio
Journal:  Addict Biol       Date:  2015-06-02       Impact factor: 4.280

8.  Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers.

Authors:  Terril L Verplaetse; Walter Roberts; Kelly E Moore; MacKenzie R Peltier; Lindsay M Oberleitner; Sherry A McKee
Journal:  J Clin Psychopharmacol       Date:  2019 Mar/Apr       Impact factor: 3.153

9.  Effects of naltrexone on cortisol levels in heavy drinkers.

Authors:  Lara A Ray; James Mackillop; Lorenzo Leggio; Marilee Morgan; Kent E Hutchison
Journal:  Pharmacol Biochem Behav       Date:  2008-09-13       Impact factor: 3.533

10.  Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial.

Authors:  Marc E Mooney; David V Herin; Joy M Schmitz; Nidal Moukaddam; Charles E Green; John Grabowski
Journal:  Drug Alcohol Depend       Date:  2008-12-05       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.